http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 09:05:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/AtaiBeckley+launches+%2460%2C000+grant+program+for+mental+health+nonprofits/26562339.html <p>AtaiBeckley Inc. (NASDAQ: ATAI) announced the launch of its Patient Impact Grant Program, which will provide three $20,000 grants to nonprofit organizations working to improve mental health outcomes.</p><p>The biotechnology company said the grants will target three areas: community support for equitable access to mental health treatments, education and stigma reduction initiatives, and ecosystem innovation and independent research. Organizations can apply for funding to support work with underserved populations, promote mental health awareness, or develop patient-informed approaches.</p><p>A review panel will select recipients, including Kevin Craig, the company's chief medical officer, Caroline Lilley, head of patient impact, and Dr. Jessica Jackson from http://www.streetinsider.com/Corporate+News/AtaiBeckley+launches+%2460%2C000+grant+program+for+mental+health+nonprofits/26562339.html Thu, 28 May 2026 09:05:42 -0400 ATAI http://www.streetinsider.com/Press+Releases/AtaiBeckley+Launches+Patient+Impact+Grant+Program+for+Mental+Health+Non-Profit+Organizations/26562074.html <ul type="disc"><li>Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research<br /></li></ul> <p>NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research.</p> <p><strong>Grant Funding Areas</strong></p> <table http://www.streetinsider.com/Press+Releases/AtaiBeckley+Launches+Patient+Impact+Grant+Program+for+Mental+Health+Non-Profit+Organizations/26562074.html Thu, 28 May 2026 09:00:00 -0400 ATAI http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Launches+Patient+Impact+Grant+Program+for+Mental+Health+Non-Profit+Organizations/26562074.html <ul type="disc"><li>Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research<br /></li></ul> <p>NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research.</p> <p><strong>Grant Funding Areas</strong></p> <table http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Launches+Patient+Impact+Grant+Program+for+Mental+Health+Non-Profit+Organizations/26562074.html Thu, 28 May 2026 09:00:00 -0400 ATAI http://www.streetinsider.com/Press+Releases/AtaiBeckley+to+Participate+in+Upcoming+Investor+Conferences+in+June+2026/26552722.html <p>NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company’s management team will participate in multiple upcoming investor conferences in June 2026.</p> <p><strong>Jefferies Global Healthcare Conference</strong></p> <ul type="disc"><li>Dates: June 2 – 4, 2026</li><li>Location: New York, NY</li><li>Participation: Fireside chat and one-on-one meetings</li><li>Presentation date and time: Wednesday, June 3, 12:15 PM ET</li><li>Webcast link: <a href="https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=fpBDEvLFcurTNSUMHyQshL" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=fpBDEvLFcurTNSUMHyQshL</a><br /></li></ul> <p><strong>Oppenheimer CNS and Neuro-Muscular Summit</strong></p> <ul http://www.streetinsider.com/Press+Releases/AtaiBeckley+to+Participate+in+Upcoming+Investor+Conferences+in+June+2026/26552722.html Wed, 27 May 2026 06:00:00 -0400 ATAI http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+to+Participate+in+Upcoming+Investor+Conferences+in+June+2026/26552722.html <p>NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company’s management team will participate in multiple upcoming investor conferences in June 2026.</p> <p><strong>Jefferies Global Healthcare Conference</strong></p> <ul type="disc"><li>Dates: June 2 – 4, 2026</li><li>Location: New York, NY</li><li>Participation: Fireside chat and one-on-one meetings</li><li>Presentation date and time: Wednesday, June 3, 12:15 PM ET</li><li>Webcast link: <a href="https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=fpBDEvLFcurTNSUMHyQshL" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=fpBDEvLFcurTNSUMHyQshL</a><br /></li></ul> <p><strong>Oppenheimer CNS and Neuro-Muscular Summit</strong></p> <ul http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+to+Participate+in+Upcoming+Investor+Conferences+in+June+2026/26552722.html Wed, 27 May 2026 06:00:00 -0400 ATAI http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Press+Releases/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html <ul><li style="text-align:justify;">Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026</li><li style="text-align:justify;">VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026</li><li style="text-align:justify;">Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder</li><li style="text-align:justify;">Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029<br/><br/></li></ul> <p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Reports+First+Quarter+2026+Financial+Results+and+Provides+Program+and+Business+Update/26473381.html Tue, 12 May 2026 08:00:00 -0400 A.50216152 A.50216683 ATAI O.38546254 O.48309657 http://www.streetinsider.com/Press+Releases/AtaiBeckley+and+PsyPAN+Receive+a+Silver+Award+in+2026+Patient+Participant+Index%2C+Reflecting+Ongoing+Commitment+to+Participant-Informed+Research/26368557.html <p>NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in <a href="https://www.globenewswire.com/Tracker?data=kml1VbgDVkTDOdwzRKygdfI-Jx1o-_TSSOhiIkM4gob_ixVqY5F2yp6sGtTQIucpuu6LmRSWPzyi7h7aXmzs3D58ePIjDG6V2otCrmKBYsy08MXtIcnjMb8yB7YOjFpZ64OZIz-2nboMsg0hgCD67DadJIHfjJ88gq9CYUVHxp0=" rel="nofollow" target="_blank">OVID Health’s 2026 Patient Participant Index (PPI),</a> in collaboration with the <a href="https://www.globenewswire.com/Tracker?data=jGyV32kSuGpkn_9NZkyVnuE1mQYe1e8Fh69fygMjsVa69bUxC_1OZcqH4Wpyj5cMfQmt3qeF6sM5gJCyUtV4mshM4OGnJrQSKXPga5IRP_b1WnMi-s3dREX5meBJBXHCLH87b6r_xwSucXPf3XSQnw==" rel="nofollow" target="_blank">Psychedelic Participant Advocacy Network (PsyPAN)</a>, in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research. The recognition highlights AtaiBeckley’s multiyear collaboration with PsyPAN to integrate the lived experiences of clinical trial participants into the http://www.streetinsider.com/Press+Releases/AtaiBeckley+and+PsyPAN+Receive+a+Silver+Award+in+2026+Patient+Participant+Index%2C+Reflecting+Ongoing+Commitment+to+Participant-Informed+Research/26368557.html Mon, 27 Apr 2026 04:05:00 -0400 ATAI http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+and+PsyPAN+Receive+a+Silver+Award+in+2026+Patient+Participant+Index%2C+Reflecting+Ongoing+Commitment+to+Participant-Informed+Research/26368557.html <p>NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in <a href="https://www.globenewswire.com/Tracker?data=kml1VbgDVkTDOdwzRKygdfI-Jx1o-_TSSOhiIkM4gob_ixVqY5F2yp6sGtTQIucpuu6LmRSWPzyi7h7aXmzs3D58ePIjDG6V2otCrmKBYsy08MXtIcnjMb8yB7YOjFpZ64OZIz-2nboMsg0hgCD67DadJIHfjJ88gq9CYUVHxp0=" rel="nofollow" target="_blank">OVID Health’s 2026 Patient Participant Index (PPI),</a> in collaboration with the <a href="https://www.globenewswire.com/Tracker?data=jGyV32kSuGpkn_9NZkyVnuE1mQYe1e8Fh69fygMjsVa69bUxC_1OZcqH4Wpyj5cMfQmt3qeF6sM5gJCyUtV4mshM4OGnJrQSKXPga5IRP_b1WnMi-s3dREX5meBJBXHCLH87b6r_xwSucXPf3XSQnw==" rel="nofollow" target="_blank">Psychedelic Participant Advocacy Network (PsyPAN)</a>, in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research. The recognition highlights AtaiBeckley’s multiyear collaboration with PsyPAN to integrate the lived experiences of clinical trial participants into the http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+and+PsyPAN+Receive+a+Silver+Award+in+2026+Patient+Participant+Index%2C+Reflecting+Ongoing+Commitment+to+Participant-Informed+Research/26368557.html Mon, 27 Apr 2026 04:05:00 -0400 ATAI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtaiBeckley+Inc.++++++++++For%3A+Apr+20++Filed+by%3A+Craig+Kevin+James/26352716.html si-local-file:///var/storage/secattach/20260422/26352716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtaiBeckley+Inc.++++++++++For%3A+Apr+20++Filed+by%3A+Craig+Kevin+James/26352716.html Wed, 22 Apr 2026 17:33:00 -0400 ATAI O.48309657 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtaiBeckley+Inc.++++++++++For%3A+Apr+20++Filed+by%3A+Craig+Kevin+James/26352716.html si-local-file:///var/storage/secattach/20260422/26352716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtaiBeckley+Inc.++++++++++For%3A+Apr+20++Filed+by%3A+Craig+Kevin+James/26352716.html Wed, 22 Apr 2026 17:33:00 -0400 ATAI O.48309657 http://www.streetinsider.com/Options/AtaiBeckley+%28ATAI%29+call+put+ratio+7.3+calls+to+1+put+with+a+focus+on+May+calls+as+share+price+up+23%25/26336642.html <p>AtaiBeckley (NASDAQ: ATAI) 30-day option implied volatility is at 107; compared to its 52-week range of 72 to 142. Call put ratio 7.3 calls to 1 put with a focus on May calls as share price up 23%.</p> http://www.streetinsider.com/Options/AtaiBeckley+%28ATAI%29+call+put+ratio+7.3+calls+to+1+put+with+a+focus+on+May+calls+as+share+price+up+23%25/26336642.html Mon, 20 Apr 2026 15:13:14 -0400 ATAI http://www.streetinsider.com/Analyst+PT+Change/AtaiBeckley+Inc+%28ATAI%29+PT+Raised+to+%2415+at+Canaccord/26333888.html (Updated - April 20, 2026 7:42 AM EDT) <p>Canaccord analyst Sumant Kulkami raised the price target on AtaiBeckley Inc (NASDAQ: ATAI) to $15.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are adjusting our model as we prepare for BPL-003 to enter Phase 3 trials this quarter and wait for VLS-01 Elumina Phase 2 data for TRD in 2H26. The key changes we are making are that we now model a price of net annual price of $30k for BPL--03 at launch (vs. ~$20k), which is more in line with Spravato's net price. Our price assumption could still be http://www.streetinsider.com/Analyst+PT+Change/AtaiBeckley+Inc+%28ATAI%29+PT+Raised+to+%2415+at+Canaccord/26333888.html Mon, 20 Apr 2026 07:42:17 -0400 ATAI http://www.streetinsider.com/Analyst+Comments/AtaiBeckley+Inc+%28ATAI%29+PT+Raised+to+%2415+at+Canaccord/26333888.html (Updated - April 20, 2026 7:42 AM EDT) <p>Canaccord analyst Sumant Kulkami raised the price target on AtaiBeckley Inc (NASDAQ: ATAI) to $15.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are adjusting our model as we prepare for BPL-003 to enter Phase 3 trials this quarter and wait for VLS-01 Elumina Phase 2 data for TRD in 2H26. The key changes we are making are that we now model a price of net annual price of $30k for BPL--03 at launch (vs. ~$20k), which is more in line with Spravato's net price. Our price assumption could still be http://www.streetinsider.com/Analyst+Comments/AtaiBeckley+Inc+%28ATAI%29+PT+Raised+to+%2415+at+Canaccord/26333888.html Mon, 20 Apr 2026 07:42:17 -0400 ATAI http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html <p>By Kamal Choudhury</p> <p>April 20 (Reuters) - Shares ‌of psychedelic drug ​developers rose ​on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic treatments and increased federal ‌funding for their research.</p> <p>Shares of AtaiBeckley jumped 28% in morning trading, while Compass ⁠Pathways climbed 37%, Enveric BioSciences surged 140% and http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html Mon, 20 Apr 2026 06:43:10 -0400 ATAI DFTX GHRS http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html <p>By Kamal Choudhury</p> <p>April 20 (Reuters) - Shares ‌of psychedelic drug ​developers rose ​on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic treatments and increased federal ‌funding for their research.</p> <p>Shares of AtaiBeckley jumped 28% in morning trading, while Compass ⁠Pathways climbed 37%, Enveric BioSciences surged 140% and http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html Mon, 20 Apr 2026 06:43:10 -0400 ATAI DFTX GHRS http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html <p>By Kamal Choudhury</p> <p>April 20 (Reuters) - Shares ‌of psychedelic drug ​developers rose ​on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic treatments and increased federal ‌funding for their research.</p> <p>Shares of AtaiBeckley jumped 28% in morning trading, while Compass ⁠Pathways climbed 37%, Enveric BioSciences surged 140% and http://www.streetinsider.com/Reuters/Psychedelic+drug+developers+rally+after+Trump+orders+FDA+to+expedite+reviews/26333519.html Mon, 20 Apr 2026 06:43:10 -0400 ATAI DFTX GHRS